After Phase 3 depression setback, Neumora pauses two trials to make changes, scraps another

Kyle LaHucik

Senior Reporter

Brain health biotech Neumora has stopped two of its Phase 3 trials in major depressive disorder to make adjustments after the first late-stage study unexpectedly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After Phase 3 depression setback, Neumora pauses two trials to make changes, scraps another

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Trump blog: Top HHS spokesperson resigns within weeks of being sworn in

ICER finds GSK inhalers offer advantages over generic competitors

Pliant calls it quits on Phase 2b idiopathic pulmonary fibrosis study

Biohaven’s ion channel drug fails pivotal bipolar mania study

Novo Nordisk signs $354M partnership with AI-guided biotech for ‘risky’ new metabolic mechanisms

The perfect storm: Why everything is in place for 2025 to be the year of GxP AI

Af­ter Phase 3 de­pres­sion set­back, Neumo­ra paus­es two tri­als to make changes, scraps an­oth­er

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

After Phase 3 depression setback, Neumora pauses two trials to make changes, scraps another